Product Description
Tirofiban is an intravenously administered nonpeptide glycoprotein IIb/IIIa receptor antagonist which specifically inhibits fibrinogen-dependent platelet aggregation and prolongs bleeding times in patients with acute coronary syndromes. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/9878994/)
Mechanisms of Action: GPIIb/IIIa Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Cyprus | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Russia | Saudi Arabia | Singapore | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Medicure
Company Location: WINNIPEG A2 R3T 6C6
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Ischemic Stroke
Phase 2: Acute Coronary Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ADJUVANT | P3 |
Recruiting |
Ischemic Stroke |
2027-03-01 |
|
| RESET | P2 |
Active, not recruiting |
Ischemic Stroke |
2023-03-30 |
|
| CTR20132880 | P2 |
Active, not recruiting |
Acute Coronary Syndrome |
None |
|
| CTR20213126 | P2 |
Not yet recruiting |
Ischemic Stroke |
None |